Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 28NIH 23INDUSTRY 15NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Refractory Differentiated Thyroid Gland Carcinoma 1

Interventions

Specimen Handling 47Magnetic Resonance Spectroscopy 38Cyclophosphamide 28Vincristine 22Radiation 19Dexamethasone 19Etoposide 18Cisplatin 18Carboplatin 17Biopsy 17Radiotherapy 16Doxorubicin 13Cytarabine 13daratumumab 12Leucovorin 12Methotrexate 11Gemcitabine 11X-Rays 10Standard of Care 10Platinum 10Docetaxel 10durvalumab 9Rituximab 9Radiotherapy, Intensity-Modulated 9Prednisone 9Practice Guidelines as Topic 9Calcium Dobesilate 91,2-diaminocyclohexaneplatinum II citrate 9merphos 8dexamethasone acetate 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × cabozantinib × 90 days × Clear all
NCT06475989 2026-05-15

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Eastern Cooperative Oncology Group

Phase 3 Recruiting
264 enrolled
Head & Neck

Refractory Differentiated Thyroid Gland Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡